AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35777275
Drug: 324 mg
RxNorm normalized name: aspirin 324 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 324 mg of VTS‐Aspirin™ and 0.5 mg/kg of oral ketamine (AOK)
Trial: 35777275
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg of oral ketamine (OK)
Trial: 32270632
Drug: Midnight-noon ebb-flow
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midnight-noon ebb-flow acupuncture combined with rehabilitation therapy
Trial: 32270632
Drug: Rehabilitation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation therapy (control group)
Trial: 34034365
Drug: High-TSH group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-TSH group (target TSH levels between 2.0 and 7.99 μIU/mL)
Trial: 34034365
Drug: Low-TSH group
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-TSH group (target TSH levels between 0.3 and 1.99 μIU/mL)
Trial: 36402359
Drug: High-dose IMRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IMRT (59.4 Gy)
Trial: 36402359
Drug: Standard-dose IMRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose IMRT (50.4 Gy)
Trial: 33555374
Drug: Fibre-enriched Leberkas
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre-enriched Leberkas meal (19.2 g of wheat fibre and resistant dextrin, fat- and energy-reduced by 30%)
Trial: 35470188
Drug: Primary radiotherapy
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary radiotherapy combined with S‐1 and nedaplatin chemotherapy (50.4 Gy + 4-6 cycles of S-1 and NPD)
Trial: 35470188
Drug: S‐1 and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐1 and nedaplatin chemotherapy (4-6 cycles)
Trial: 34810107
Drug: Inspiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory muscle training + sensorimotor physical therapy (45 min sensorimotor + 15 min inspiratory muscle training for 18 sessions over six weeks)
Trial: 34041615
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (six-step music therapy), n=50
Trial: 32205463
Drug: Nivolumab 1
RxNorm normalized name: nivolumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg + RT (30 Gy in 10 fractions)
Trial: 32205463
Drug: Nivolumab 1
RxNorm normalized name: nivolumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg + RT (27 Gy in 3 fractions)
Trial: 34061144
Drug: Reduced-dose prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose prednisolone (0.5 mg/kg/d) plus rituximab (375 mg/m2/wk, 4 doses)
Trial: 34061144
Drug: High-dose prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prednisolone (1 mg/kg/d) plus rituximab
Trial: 34061144
Drug: Reduced-dose prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose prednisolone (0.5 mg/kg/d) plus rituximab
Trial: 32334034
Drug: Concurrent weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Concurrent weekly cisplatin 40 mg/m2 with escalating doses of gemcitabine (50, 75, 100, or 125 mg/m2) plus IG‐IMRT (45‐47.6 Gy, 25‐28 fractions to the pelvis ± paraortic nodes with simultaneous nodal boost to 53.2‐59.4 Gy, 28 fractions)
Trial: 32334034
Drug: IG‐IMRT with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IG‐IMRT with concurrent chemotherapy
Trial: 33171113
Drug: Leukocyte‐ and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocyte‐ and platelet‐rich fibrin (L‐PRF)
Trial: 35236391
Drug: morphine sulphate
RxNorm normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: morphine sulphate 5 mg twice daily for 14 days
Trial: 35236391
Drug: placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo twice daily
Trial: 32633901
Drug: Attention Bias
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention Bias Modification (ABM) - eight sessions of twice-weekly training (n=49)
Trial: 32216084
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate (SXB) administered in two equally divided doses over two nights; dose 1 was half of dose 2, administered > 2 hours after the evening meal and ≥ 4 hours after dose 1.
Trial: 36054974
Drug: Cyproheptadine HCl
RxNorm normalized name: cyproheptadine HCl
DrugBank: Cyproheptadine (DB00434)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyproheptadine HCl (4 mg BID to 8 mg TID over 3 weeks)
Trial: 36054974
Drug: Placebo (matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matched doses)
Trial: 32803720
Drug: First-line doublet
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line doublet chemotherapy with bevacizumab
Trial: 32803720
Drug: First-line doublet
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line doublet chemotherapy without bevacizumab
Trial: 33246371
Drug: Thinking for
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thinking for a Change cognitive behavioral program with greater program dosage
Trial: 33246371
Drug: Traditional classroom
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional classroom administration of the Thinking for a Change program
Trial: 36121664
Drug: Men with
RxNorm normalized name: Peptamen with Prebio Vanilla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men with PSA ≥3 to 4 ng/ml
Trial: 36121664
Drug: Men with
RxNorm normalized name: Peptamen with Prebio Vanilla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men with a history of digital rectal examination or PSA testing prior to recruitment
Trial: 33611087
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg regular, oral sustained-release morphine twice daily for four weeks
Trial: 34895843
Drug: Posaconazole with
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole with other antifungal prophylaxis (Group-3, n = 142)
Trial: 34895843
Drug: Other antifungal
RxNorm normalized name: Other antifungals for topical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antifungal prophylaxis (Group-4, n = 91)
Trial: 34895843
Drug: No antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antifungal prophylaxis (Group-1, n = 203)
Trial: 35207411
Drug: Melatonin 2
RxNorm normalized name: melatonin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 2 mg administered orally for 12 weeks
Trial: 34663379
Drug: XR-naltrexone treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XR-naltrexone treatment
Trial: 33191260
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) 650 mg
Trial: 32219517
Drug: CAM users
RxNorm normalized name: phendimetrazine tartrate Oral Tablet [Cam-Metrazine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAM users declining conventional cancer therapy (CCT)
Trial: 33159163
Drug: Fish-oil (FO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil (FO) supplementation (215 mg DHA + 285 mg EPA)
Trial: 33159163
Drug: Control corn-oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control corn-oil capsules (without n‐3 LCPs)
Trial: 37614053
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination therapy (telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg)
Trial: 37614053
Drug: Dual combination
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual combination therapy (telmisartan 40 mg/amlodipine 5 mg)
Trial: 33787382
Drug: Early steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early steroid withdrawal (ESW)
Trial: 35473650
Drug: Present-centered group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Present-centered group therapy (TAU)
Trial: 32197342
Drug: Five-day intensive
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-day intensive holiday cooking program followed by six weeks of weekly meal kits with Facebook support groups
Trial: 35239885
Drug: Integrated experiential
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated experiential learning of traditional Chinese and Western medicine
Trial: 34508839
Drug: GLS in
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GLS in patients on baseline angiotensin convertase enzyme inhibitors
Trial: 34508839
Drug: GLS in
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GLS in patients on baseline beta-blockers
Trial: 32940847
Drug: CEF (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEF (cyclophosphamide 75 mg/m2 orally for 14 days, epirubicin 60 mg/m2 and fluorouracil IV days one and eight for six cycles)
Trial: 32940847
Drug: ddEC/T (dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ddEC/T (dose-dense epirubicin 120 mg/m2 and cyclophosphamide IV every 2 weeks for six cycles with concurrent G-CSF then paclitaxel every 2 weeks for four cycles)
Trial: 32940847
Drug: AC/T (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC/T (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 3 weeks for four cycles then four cycles q3 weekly paclitaxel 175 mg/m2)
Trial: 34034067
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (0.5-0.75 mg/kg) administered over 1-2 weeks, with four infusions.
Trial: 32152169
Drug: 430 mg
RxNorm normalized name: urea 430 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 430 mg olive oil (placebo)
Trial: 35922522
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose IV salbutamol (15 mcg/kg, max. 750 mcg)
Trial: 35922522
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose IV salbutamol
Trial: 34726262
Drug: Nemolizumab 60
RxNorm normalized name: Nemolizumab
DrugBank: Nemolizumab (DB15252)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab 60 mg every 4 weeks (Q4W) with concomitant topical treatments
Trial: 34810349
Drug: Simvastatin Gel
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin Gel (SG)
Trial: 36476355
Drug: Carrier oil
RxNorm normalized name: Carrier oil-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrier oil inhalation (Control group, n=48)
Trial: 35140195
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg per day from admission to discharge)
Trial: 34714194
Drug: Nifedipine gastrointestinal
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine gastrointestinal therapeutic system (GITS, 30‐60 mg)
Trial: 34714194
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (both amlodipine and nifedipine)
Trial: 32857027
Drug: Collagen-based bioinductive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen-based bioinductive implant
Trial: 34261489
Drug: Lettuce (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lettuce (100 g) with moderately high-fat meal
Trial: 34261489
Drug: Watercress (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watercress (100 g) with moderately high-fat meal
Trial: 616871171
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg atorvastatin once daily for 6 months
Trial: 36271753
Drug: office-based vergence/accommodative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: office-based vergence/accommodative therapy
Trial: 33884674
Drug: High hemoglobin
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High hemoglobin target (>12.5 g/dL)
Trial: 33884674
Drug: Low hemoglobin
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low hemoglobin target (<10.5 g/dL)
Trial: 35534590
Drug: 0.3 M
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 M sodium chloride solution
Trial: 35534590
Drug: 0.5 M
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 M sodium chloride solution
Trial: 36164077
Drug: Loncastuximab tesirine
RxNorm normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loncastuximab tesirine (0.15 mg/kg) + rituximab (375 mg/m2) for 2 cycles, then Loncastuximab (0.075 mg/kg) + rituximab (375 mg/m2) for up to 6 additional cycles.
Trial: 33131170
Drug: Fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2 laser combined with L-GFs
Trial: 35769842
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1200 mg daily for 10 days
Trial: 35986297
Drug: Acupuncture based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture based on syndrome differentiation with donepezil (5 mg/day) for 12 weeks
Trial: 35970518
Drug: Fluticasone furoate/umeclidinium/vilanterol
RxNorm normalized name: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg
Trial: 32162970
Drug: Fluticasone furoate/umeclidinium/vilanterol
RxNorm normalized name: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/umeclidinium/vilanterol (FF/VI) 100/25 μg
Trial: 34774885
Drug: FDY-5301 (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDY-5301 (2.0 mg/kg)
Trial: 34774885
Drug: FDY-5301 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDY-5301 (0.5 mg/kg and 1.0 mg/kg)
Trial: 34621380
Drug: Asthma patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asthma patients with CC genotype
Trial: 33526271
Drug: SURE RAB™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SURE RAB™ (inactivated cell culture derived rabies vaccine)
Trial: 33526271
Drug: VERORAB (approved
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VERORAB (approved rabies vaccine)
Trial: 34989778
Drug: 5-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-day regimen of postoperative prophylactic intravenous cephalosporin (cefazolin or cefuroxime)
Trial: 34989778
Drug: 1-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-day regimen of postoperative prophylactic intravenous cephalosporin (cefazolin or cefuroxime)
Trial: 33073449
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (20 g day−1 for 5 days)
Trial: 33348935
Drug: PRP intradermal
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP intradermal injection
Trial: 33348935
Drug: FCL followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FCL followed by topical PRP
Trial: 33348935
Drug: Microneedling followed
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedling followed by topical PRP
Trial: 35781816
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg VE
Trial: 35781816
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg VE
Trial: 35781816
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg VE
Trial: 35781816
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg VE
Trial: 33654316
Drug: PVP-I 0.6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVP-I 0.6% eye drops four times/daily for 20 days
Trial: 33654316
Drug: Hyaluronate-based tear
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronate-based tear substitutes four times/daily for 20 days
Trial: 32246682
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac (50 mg twice daily)
Trial: 32246682
Drug: Transdermal diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal diclofenac patch (100 mg once daily)
Trial: 33038280
Drug: Soluble leptin
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble leptin receptor (sOB-R)
Trial: 33095849
Drug: Systemic heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic heparin anticoagulation (n=296)
Trial: 35142643
Drug: DRL_TZ (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRL_TZ (6 mg/kg, single intravenous infusion)
Trial: 35142643
Drug: Herceptin® (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herceptin® (6 mg/kg, single intravenous infusion)
Trial: 34444121
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal treatment (NSPT) with community health worker (CHW) strategy
Trial: 36151343
Drug: Mechanical bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechanical bowel preparation (MBP) with oral antibiotics (OA) using Alfa Normix®
Trial: 36151343
Drug: Mechanical bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechanical bowel preparation (MBP) alone
Trial: 32502588
Drug: Tapinarof cream
RxNorm normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapinarof cream 0.5%
Trial: 32502588
Drug: Tapinarof cream
RxNorm normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapinarof cream 1%
Trial: 32502588
Drug: Tapinarof cream
RxNorm normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapinarof cream 0.5% once or twice daily
Trial: 34216454
Drug: Lidocaine 1%
RxNorm normalized name: LIDOCAINE 1% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1% with epinephrine (40 ml)
Trial: 34216454
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% with epinephrine (20 ml)
Trial: 36307989
Drug: Topical gentamicin
RxNorm normalized name: gentamicin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gentamicin cream delivered via the platform wound device (PWD)
Trial: 36153456
Drug: Medication +
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication + Thunder-fire moxibustion
Trial: 33401330
Drug: Prasugrel standard-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel standard-dose (10 mg)
Trial: 33401330
Drug: Prasugrel de-escalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel de-escalation strategy (5 mg and PFT-guided)
Trial: 35958679
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg esketamine
Trial: 33352584
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (8 IU, self-administered up to thrice daily for 4 weeks)
Trial: 33125189
Drug: MK-1654 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1654 (100 mg, 300 mg intramuscular; 300 mg, 1000 mg, 3000 mg intravenous)
Trial: 32533791
Drug: 2 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg.kg‐1 intranasal dexmedetomidine
Trial: 32533791
Drug: 1 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg.kg‐1 intravenous dexmedetomidine
Trial: 36107220
Drug: Rifampin 600
RxNorm normalized name: rifampin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg
Trial: 36274185
Drug: CBTv-based EMI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBTv-based EMI in addition to treatment as usual (TAU)